HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

72.750

-1.850-2.48%

Volume:1.10M

Turnover:81.85M

Market Cap:14.48B

PE:-51.54

High:76.250

Open:75.050

Low:72.600

Close:74.600

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:1.05

T/O Rate:0.55%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.412

ROE:-27.61%

ROA:-9.92%

PB:9.80

PE(LYR):-51.54

PS:70.01

Loading ...

Overview Company News Filings

Nanjing Leads Rises on Clinical Study Progress on Cancer Treatment Drug

Leads Biolabs Advances Opamtistomig Phase II First-Line ESCC Trial into Expansion Stage

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Phase Ii Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

THOMSON REUTERS

Hong Kong Stock Flash | LEADS BIOLABS-B (09887) Surges Over 5% in Morning Trade as Phase II Trial for First-Line ESCC Advances to Expansion Stage

Movement Alert｜LEADS BIOLABS-B Rises 5.14% in Regular Trading, Phase II ESCC Study Enters Expansion Stage

LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase

Leads Biolabs Advances PD-L1/4-1BB Bispecific Antibody LBL-024 into Expansion Phase of Phase II First-Line ESCC Trial

Bulletin Express

Leads Biolabs' Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Nda Accepted by Nmpa, Poised to Become World's First Approved 4-1Bb-Targeting Therapy

THOMSON REUTERS

Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody

Nanjing Leads Biolabs Says NMPA Accepts NDA for LBL-024 in Advanced EP-NEC

Nanjing Leads Biolabs Co - Nmpa Accepts Nda for Lbl-024 (Opamtistomig) for Advanced Ep-Nec

THOMSON REUTERS

Movement Alert｜LEADS BIOLABS-B Falls 5.65% in Regular Trading, Trading at HK$71.95

Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published

LEADS BIOLABS-B (09887) Triggers Option Exercise to Secure LBL-051 License

Nanjing Leads Biolabs Says Oblenio Exercises LBL-051 License Option, Triggering USD 10 Million Fee

Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation

Bulletin Express

Nanjing Leads Biolabs Schedules Board Meeting to Review Interim Results, Dividend Recommendation

Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum

Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/09887/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":72.75,"timestamp":1787720989766,"preClose":74.6,"halted":0,"volume":1096500,"delay":0,"changeRate":-0.024798927613940945,"floatShares":198000000,"shares":199000000,"eps":-1.4115812830283359,"marketStatus":"Trading","change":-1.85,"latestTime":"08-26 13:09:51","open":75.05,"high":76.25,"low":72.6,"amount":81854135,"amplitude":0.048928,"askPrice":72.75,"askSize":9800,"bidPrice":72.7,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":-1.3730836116730176,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787731800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":74.6,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"volumeRatio":1.050638,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.411581,"volumeRatio":1.050638,"shares":199000000,"dividePrice":0,"high":76.25,"amplitude":0.048928,"preClose":74.6,"low":72.6,"week52Low":44.72,"pbRate":"9.80","psRate":"70.01","week52High":97.5,"institutionHeld":0,"latestPrice":72.75,"committee":-0.75,"eps":-1.4115812830283359,"divideRate":0,"volume":1096500,"delay":0,"ttmEps":-1.3730836116730176,"open":75.05,"prevYearClose":51,"prevWeekClose":71.2,"prevMonthClose":53.4,"prevQuarterClose":49.32,"fiveDayClose":70.45,"twentyDayClose":51.6,"sixtyDayClose":60.6,"earningDate":1788105600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-08-25","current":-53.240281,"percent":0.113208,"low":-76.458084,"twenty":-45.51173,"median":-39.866177,"eighty":-34.570466,"high":-30.202688,"avg":-42.029119,"sd":9.861951,"marketCap":14837328280},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-25","current":-51.029822,"twenty":-45.51173,"median":-39.866177,"eighty":-34.570466,"marketCap":14837328280}],"updateTime":1787717631035},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662531786","title":"Nanjing Leads Rises on Clinical Study Progress on Cancer Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662531786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662531786?lang=en_us&edition=fundamental","pubTime":"2026-08-25 13:43","pubTimestamp":1787636594,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads rises on clinical study progress on cancer treatment drug** Shares of Nanjing Leads Biolabs9887.HKjump 9.2% to HK$75.4, their biggest intraday pct gain since July 15** The China-based oncology and autoimmune therapies developer says Phase II clinical study of its drug candidate LBL-024 as a first-line treatment for patients with metastatic esophageal squamous cell carcinoma has completed the safety lead-in stage and has advanced to the combination treatmentexpansion stage** LBL-024 has demonstrated a favourable safety and tolerability profile in about 800 patients treated to date, supporting its development as a potential next-generation immuno-oncology backbone therapy, says Nanjing Leads** YTD, stock up 46.2%, Hang Seng Biotech Index.HSBIOup 11.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M047:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200258","title":"Leads Biolabs Advances Opamtistomig Phase II First-Line ESCC Trial into Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662200258?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624721,"startTime":"0","endTime":"0","summary":"Leads Biolabs advances Opamtistomig Phase II first-line ESCC trial into expansion stageNanjing Leads Biolabs moved its Phase II study of Opamtistomig into an expansion stage for first-line esophageal ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL2FJpxz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","IE00BQXX3C00.GBP","LU2210150020.SGD","LU2095319765.USD","BCDF","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014021.USD","BK4112","HK0000500386.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BQXX3D17.EUR","HK0000252152.HKD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BQXX3F31.USD","SG9999014039.USD","BK1161","LU0314104364.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004752","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Phase Ii Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662004752?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7XQSTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131567775","title":"Hong Kong Stock Flash | LEADS BIOLABS-B (09887) Surges Over 5% in Morning Trade as Phase II Trial for First-Line ESCC Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131567775","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131567775?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:16","pubTimestamp":1787624183,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) shares climbed more than 5% during Tuesday morning trading, last up 4.42% at HK$72.10 with turnover reaching HK$33.55 million.The company announced that its self-developed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","BK4585","HK0000252160.HKD","09887","KCAI","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163673761","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.14% in Regular Trading, Phase II ESCC Study Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1163673761","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163673761?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:55","pubTimestamp":1787622946,"startTime":"0","endTime":"0","summary":"On August 25, LEADS BIOLABS-B rose 5.14% in regular trading, trading at HK$72.4/share, with turnover of approximately HK$28.4 million. The stock gained on news that its core drug candidate Vilixin...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Surges on Vilixin ESCC Phase II Expansion","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121426329","title":"LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1121426329","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121426329?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:00","pubTimestamp":1787612419,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the Phase II clinical study of its self-developed investigational drug Vilitrin (Opasotiumumab, a PD-L1/4-1BB bispecific antibody, LBL-024) for the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","HK0000252160.HKD","HK0000500386.USD","LU1169590202.USD","HK0000252152.HKD","BK4023","BK1161","LU1169589451.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174574289","title":"Leads Biolabs Advances PD-L1/4-1BB Bispecific Antibody LBL-024 into Expansion Phase of Phase II First-Line ESCC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1174574289","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174574289?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:46","pubTimestamp":1787611599,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed bispecific antibody LBL-024 (Opamtistomig) has completed the safety lead-in portion of a Phase II study in first-line...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326621","title":"Leads Biolabs' Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Nda Accepted by Nmpa, Poised to Become World's First Approved 4-1Bb-Targeting Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661326621?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:21","pubTimestamp":1787304089,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148838562","title":"Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1148838562","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148838562?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:50","pubTimestamp":1787302229,"startTime":"0","endTime":"0","summary":"Leads Biolabs-B (09887) has announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has formally accepted the company's independently developed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","IPOS","LU1169589451.USD","HK0000252152.HKD","BK4023","PD","09887","BK1161","HK0000500386.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661655402","title":"Nanjing Leads Biolabs Says NMPA Accepts NDA for LBL-024 in Advanced EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661655402","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661655402?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:42","pubTimestamp":1787301756,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NECNanjing Leads Biolabs’ NMPA drug review center accepted an NDA for LBL-024 (Opatlisumab), a PD-L1/4-1BB bispecific, in EP-NEC.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLc4nHQt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265547","title":"Nanjing Leads Biolabs Co - Nmpa Accepts Nda for Lbl-024 (Opamtistomig) for Advanced Ep-Nec","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661265547?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:42","pubTimestamp":1787301730,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160907287","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.65% in Regular Trading, Trading at HK$71.95","url":"https://stock-news.laohu8.com/highlight/detail?id=1160907287","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160907287?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:43","pubTimestamp":1787276590,"startTime":"0","endTime":"0","summary":"On August 21, LEADS BIOLABS-B fell 5.65% in regular trading, trading at HK$71.95/share, with turnover of HK$29.23 million.Within the Biotechnology sector where LEADS BIOLABS-B belongs, the sector...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143205687","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","url":"https://stock-news.laohu8.com/highlight/detail?id=1143205687","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143205687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:58","pubTimestamp":1787194735,"startTime":"0","endTime":"0","summary":"On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198582483","title":"LEADS BIOLABS-B (09887) Triggers Option Exercise to Secure LBL-051 License","url":"https://stock-news.laohu8.com/highlight/detail?id=1198582483","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198582483?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:44","pubTimestamp":1787179452,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that Oblenio Bio, Inc. (NewCo) has officially exercised its option to retain the exclusive license for LBL-051, marking a significant step forward in their...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660769234","title":"Nanjing Leads Biolabs Says Oblenio Exercises LBL-051 License Option, Triggering USD 10 Million Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2660769234","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660769234?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:16","pubTimestamp":1787177768,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Oblenio exercises LBL-051 license option, triggering USD 10 million feeOblenio exercised its option to retain the worldwide license for LBL-051, triggering a one-time US$ 10","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL3gmbQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161859865","title":"Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation","url":"https://stock-news.laohu8.com/highlight/detail?id=1161859865","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161859865?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:28","pubTimestamp":1787135308,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes: 1. Reviewing and approving the interim financial results of Leads...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660384444","title":"Nanjing Leads Biolabs Schedules Board Meeting to Review Interim Results, Dividend Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660384444","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660384444?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:11","pubTimestamp":1787134271,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs schedules board meeting to review interim results, dividend recommendationNanjing Leads Biolabs will hold a board meeting on Aug. 31, 2026.Directors are set to review interim res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL9sLqRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114260368","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1114260368","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114260368?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:55","pubTimestamp":1786931757,"startTime":"0","endTime":"0","summary":"On August 17, LEADS BIOLABS-B rose 5.18% in regular trading, trading at HK$76.95/share, with turnover of HK$64.37 million.The rise extends recent momentum fueled by a series of clinical milestones....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Dense Pipeline Catalysts Continue to Drive Momentum","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145060311","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1145060311","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145060311?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:24","pubTimestamp":1786688645,"startTime":"0","endTime":"0","summary":"On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.The movement was driven by a cluster of recent positive developments. On August...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises, Multiple Pipeline Catalysts Drive Positive Sentiment","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657509468","title":"Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657509468","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657509468?lang=en_us&edition=fundamental","pubTime":"2026-08-06 12:57","pubTimestamp":1785992261,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads Biolabs jumps on progress of tumor antibody treatment** Shares of Nanjing Leads Biolabs9887.HKjump 8.3% to HK$62.85, the highest level since July 24** Stock of the China-based oncology therapies developer set for the biggest one-day pct gain since July 15** Company says Phase II clinical study evaluating its bispecific antibody PD-L1/4-1BB and Opamtistomig  for treatment of first-line hepatocellular carcinoma , or malignant tumor, has completed safety run in phase assessment review and has successfully entered expansion phase** Preliminary data show that Opamtistomig in combination with bevacizumab has demonstrated encouraging efficacy signals in patients with HCC with a favorable overall safety profile and good tolerability - co** YTD, stock up 23.1%, Hang Seng Biotech Index.HSBIOup 1.5%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N443044:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":137,"code":"91000000","status":"200"}]}}